BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18625954)

  • 1. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
    Ohguro N; Hashida N; Tano Y
    Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
    [No Abstract]   [Full Text] [Related]  

  • 2. [Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection].
    Watanabe K; Arai A; Takase H; Takahashi H; Iwanaga Y; Sugamoto Y; Sugita S; Mochizuki M; Miura O
    Rinsho Ketsueki; 2009 Mar; 50(3):182-6. PubMed ID: 19352085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
    Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
    Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful long-term control of lymphomatous meningitis with intraventricular rituximab.
    Birnbaum T; Baumgarten Lv; Dudel C; Straube A
    J Clin Neurosci; 2014 Feb; 21(2):356-8. PubMed ID: 24054402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of central nervous system lymphoma following transplantation using monoclonal antibody and ganciclovir].
    Hansen PB; Al-Farra G
    Ugeskr Laeger; 2010 Oct; 172(42):2907-8. PubMed ID: 21040668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab.
    Maximiano Alonso C; Sánchez Ruiz AC; Cantos Sánchez de Ibargüen B; Méndez García M; Ronco IS; Provencio Pulla M
    Clin Transl Oncol; 2010 Oct; 12(10):701-3. PubMed ID: 20947485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab.
    Go A; Venugopal P; Loew J; Djordjevic D
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):439-41. PubMed ID: 16981666
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab for early-stage diffuse large-B-cell lymphoma.
    Friedberg JW
    Lancet Oncol; 2006 May; 7(5):357-9. PubMed ID: 16648037
    [No Abstract]   [Full Text] [Related]  

  • 9. Ocular involvement as first sign of isolated CNS relapse in diffuse large B-cell lymphoma.
    Ferrari A; Luppi M; Lazzerini A; Potenza L; Cavallini GM; Torelli G
    Lancet Oncol; 2006 Mar; 7(3):274. PubMed ID: 16510339
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical review: treatment of vitreoretinal lymphoma.
    Pe'er J; Hochberg FH; Foster CS
    Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraocular rituximab.
    Singh AD; Peereboom DM
    Eye (Lond); 2007 Dec; 21(12):1453-4. PubMed ID: 18159211
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab for intraocular lymphoma.
    Itty S; Pulido JS
    Retina; 2009 Feb; 29(2):129-32. PubMed ID: 19202422
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma in immunoprivileged sites: association of vitreoretinal, testicular and central nervous system lymphoma.
    Riemens A; Missotten T; Baarsma S; Vidovic-Valentincic N; Novac-Andrejcic K; Erckens R; Kuijpers R; Lokhorst H; Rothova A
    Acta Ophthalmol; 2014 Mar; 92(2):e159-60. PubMed ID: 23819861
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnostic criteria for primary ocular lymphoma.
    Arcinue CA; Hochberg F; Neumann R; Foster CS
    Ophthalmology; 2013 Mar; 120(3):646-646.e2. PubMed ID: 23714608
    [No Abstract]   [Full Text] [Related]  

  • 15. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
    Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
    Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular use of rituximab.
    Kitzmann AS; Pulido JS; Mohney BG; Baratz KH; Grube T; Marler RJ; Donaldson MJ; O'Neill BP; Johnston PB; Johnson KM; Dixon LE; Salomao DR; Cameron JD
    Eye (Lond); 2007 Dec; 21(12):1524-7. PubMed ID: 17464308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
    Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
    JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
    Cheah CY; Seymour JF
    Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab for bone lymphoma.
    Savage DG; Staron R
    Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.